Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines-Reference-Cited by-同舟云学术

Regulatory density as a means to refine current regulatory approaches for increasingly complex medicines

Published:2021-10 Issue:10 Volume:26 Page:2221-2225
ISSN:1359-6446
Container-title:Drug Discovery Today
language:en
Short-container-title:Drug Discovery Today

Author:

Klein Kevin,Stolk Pieter,De Bruin Marie Louise,Leufkens Hubert

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology

Reference24 articles.

1. Regulation (EC) No 1394/2007 of the European Parliament and of the Council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2007:324:0121:0137:en:PDF. Published November 13, 2007. Accessed April 5, 2021

2. Health systems governance in Europe: the role of European Union Law and Policy;Mossialos,2010

3. Known knowns, known unknowns, unknown unknowns: the predicament of evidence-based policy;Pawson;Am J Eval,2011

4. Immunogenicity of therapeutic proteins. Part 3: impact of manufacturing changes;Sharma;Biotechnol Adv,2007

5. Drift, evolution, and divergence in biologics and biosimilars manufacturing;Ramanan;BioDrugs,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synthetic polypeptides using a biologic as a reference medicinal product – the European landscape of regulatory approvals;Frontiers in Medicine;2024-04-12

2. Regulatory Science Approach in Pharmaceutical Development of Follow-on Versions of Non-Biological Complex Drug Products;Journal of Pharmaceutical Sciences;2022-10

3. Regulatory Flexibilities and Guidances for Addressing the Challenges of COVID-19 in the EU: What Can We Learn from Company Experiences?;Therapeutic Innovation & Regulatory Science;2022-02-07